In this issue:
The clinical relevance of viral factors in HCC development
Combination therapy needed in chronic HBV?
Neurocognitive benefits with HCV therapy
Mericitabine + PegIFNα-2a/RBV in treatment-naïve HCV G1/4
IL28B CT/TT: start treatment early
A potential prophylactic HCV vaccine
Risk prediction models for cirrhosis and HCC
Transient elastoplasty: unreliable for accurate fibrosis staging
HBx protein: effect on hepatocyte proliferation
miR-122 reflects antiviral therapy success
Please login below to download this issue (PDF)